Inotiv, Inc. to leverage TruVivo^® 2D+ hepatic system within its Discovery and Translational Sciences business to accelerate development of safer, more effective therapies through human-relevant science

In a joint press release, Inotiv, Inc. announces their strategic initiative to leverage LifeNet Health’s proprietary TruVivo® 2D+ hepatic system within its Discovery and Translational Sciences business to address critical challenges in drug development and enable better predictions of human responses to new therapies.

LifeNet Health Selected by the Henry M. Jackson Foundation to Recover Biospecimens to Study the Effects of CTE in Military Personnel

The largest Department of Defense-funded CTE scientific research project at USUHS, this study aims to advance treatment options for U.S. service members over a five-year period

TruVivo Named Cell Biology Product of the Year

LOS ANGELES (Nov. 8, 2023) — TruVivo™, a pioneering all-human 2D+ hepatic system that supports ADME/DMPK, toxicology and disease modeling applications, has been selected as the Cell Biology Product of the Year in the second annual BioTech Breakthrough Awards program.

LifeNet Health LifeSciences partners with CN Bio to set a new standard for cell quality and performance

Virginia Beach, Va. (Sept. 6, 2023) — Microphysiological systems hold the promise of revolutionizing compound discovery and safety testing — but only if researchers have access to high-quality, reliable 3D cells. LifeNet Health LifeSciences has been at the forefront of addressing this challenge, and recently the organization took another key step by entering into an agreement to supply and distribute hepatic cells to CN Bio, a leading organ-on-a-chip company that manufactures single- and multi-organ MPS platforms.

LifeNet Health LifeSciences launches TruVivo, a pioneering all-human 2D+ hepatic system, to revolutionize compound discovery

Virginia Beach, Va. (April 4, 2023) – LifeNet Health LifeSciences, the leader in all-human research solutions, today launched TruVivo, a pioneering all-human cell-based liver system, to support vital drug and compound development and discovery. TruVivo is the biggest co-culture advancement in more than a decade, offering stable, reliable results - well to well, experiment to experiment, and user to user.

LifeNet Health LifeSciences launches new, human-relevant Cell-Based Assay Service for drug and compound discovery

Virginia Beach, Va. (Aug. 1, 2022) - LifeNet Health LifeSciences, a leader in all-human biomedical research solutions, is launching a new Cell-Based Assay Service following the acquisition of biotechnology firm IONTOX. These new in vitro screening options offer alternatives to animal testing that support safer, more effective novel compound discovery – providing a new level of human relevance and predictability, while furthering LifeNet Health’s commitment to improve lives through the gift of donation.

LifeNet Health LifeSciences will showcase innovative all-human research solutions at SOT ToxExpo

• Featuring pre-clinical research solutions to include an all-human triculture model, thyrocytes for use in 3D models, and genotyped human hepatocytes
• A series of engaging events during SOT will offer researchers opportunities to connect directly with LifeNet Health LifeSciences subject matter experts

Virginia Beach, Va.

Pure MHC, LLC Announces Launch of its Peptide HLA Immunotherapy Data Resource following Collaboration with LifeNet Health

March 16, 2021

Austin, Texas, USA, March 16, 2021 -- Pure MHC, LLC, a target discovery and development company, today announced the launch of its Peptide HLA Immunotherapy Data Resource (“PHIDR”), built through its collaboration with a trusted provider of transplant solutions and a leader in regenerative medicine, LifeNet Health.

LifeNet Health LifeSciences highlights innovative human cell- and tissue-based solutions at 2021 Society of Toxicology ToxExpo

March 12, 2021

VIRGINIA BEACH, Va. (March 12, 2021) — LifeNet Health LifeSciences will showcase its portfolio of innovative human cell- and tissue-based research solutions — including the new, all-human Tri-Culture model, thyrocytes for use in 3D models and genotyped human hepatocytes — at the Society of Toxicology (SOT) virtual annual meeting and ToxExpo at booth #1322. LifeSciences provides researchers human-relevant research solutions to optimize outcomes and speed the drug discovery process.

LifeNet Health LifeSciences has isolated primary human lung cells to aid and accelerate efforts in COVID-19 drug development

February 3, 2021

VIRGINIA BEACH, Va. (Feb. 3, 2021) — LifeNet Health LifeSciences has successfully isolated three types of primary human lung epithelial cells from a single donor. One of the three types, alveolar epithelial type II cells, are of particular interest to scientists due to their applicability for respiratory disease research. LifeNet Health’s scientists have also isolated the bronchial and small airway epithelial cells, which are critical for the first lines of defense in protecting the lungs.